Figure 6.

Binding of peptide FLPNF to mTOR and solution structure of the peptide FLPNF-FRB-domain complex. (A) Flow cytometry results revealed the peptide FLPNF binds to mTOR. (B) The ribbon model (left) and the surface view (right) of the mTOR inhibitor peptide FLPNF docked into the binding site on the FRB domain. (C) The localization and conformation of rapamycin bound to the FRB domain in the FKBP12-rapamycin-FRB ternary complex (Choi et al., 1996). In (D), the Peptide FLPNF bound to the FRB domain adopts a position similar to that for rapamycin. The orientation of the FRB domain was same in (B–D). (E, F) The predicted computational model of the peptide FLPNF-FRB-domain complex. Peptide FLPNF is shown in a stick model, the protein residues are represented in a ribbon model, and hydrogen-bonds appear as yellow dotted lines.